CHESTNUT RIDGE, N.Y.,
May 26, 2015 /PRNewswire/
-- Par Specialty Pharmaceuticals, a division of Par
Pharmaceutical, Inc., today announced the launch of
Cortisporin®-TC Otic Suspension (colistin sulfate -
neomycin sulfate - thonzonium bromide - hydrocortisone acetate otic
suspension). Cortisporin®-TC Otic Suspension is
indicated for the treatment of superficial bacterial infections of
the external auditory canal (otitis externa), caused by organisms
susceptible to the action of the antibiotics; and for the treatment
of infections of mastoidectomy and fenestration cavities, caused by
organisms susceptible to the antibiotics.
Cortisporin®-TC Otic Suspension is the only treatment
for otitis externa that contains thonzonium bromide, an ingredient
that penetrates discharge to allow colistin (polymixin E),
neomycin, and hydrocortisone to contact infected tissue.
"The Par Specialty sales force will build greater awareness of a
product that has long been a trusted remedy for outer ear
infections, also known as swimmer's ear," said Paul V. Campanelli, chief executive officer of
Par Pharmaceutical Companies, Inc. "Therefore, the launch of
Cortisporin®-TC has been timed to coincide with the
traditional start of summer, Memorial
Day weekend."
Otitis externa is inflammation of the external ear canal, which
is the tube between the outer ear and eardrum, and can often be
infected. Otitis externa is often referred to as "swimmer's
ear" because repeated exposure to water can make the ear canal more
vulnerable to inflammation.
Cortisporin®-TC Otic Suspension is supplied in a 10
mL bottle. A sterilized dropper-cap assembly for use on the
bottle of suspension is included in the package.
Important Information About Cortisporin®-TC Otic
Suspension
Cortisporin®-TC Otic Suspension is contraindicated in
patients with a hypersensitivity to any of its components, should
not be used if a cutaneous viral infection is suspected or known to
exist and should be used cautiously in patients with a perforated
tympanic membrane. Neomycin can cause ototoxicity therefore
therapy should be limited to 10 consecutive days and occasionally
causes skin sensitization. The safety and effectiveness of
Cortisporin-TC in infants below one year of age have not been
established. For full prescribing information, visit
www.parpharm.com
About Par Pharmaceutical Companies, Inc.
Par is a specialty pharmaceutical company that develops,
manufactures and markets safe, innovative and cost-effective
pharmaceuticals that help improve patient quality of life.
Par Pharmaceutical offers a line of high-barrier-to-entry generic
drugs, while Par Specialty Pharmaceuticals provides niche,
innovative brands. Par Sterile Products develops,
manufactures and markets both branded and generic aseptic
injectable pharmaceuticals. For press release and other
company information, visit www.parpharm.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/par-specialty-pharmaceuticals-launches-cortisporin-tc-otic-suspension-300088560.html
SOURCE Par Pharmaceutical Companies